Abalos Therapeutics

About:

Abalos Therapeutics is an Essen, Germany-based developer of novel immuno-virotherapies against cancer.

Top Investors: HTGF | High-Tech Gruenderfonds, Seventure Partners, NRW.BANK, coparion, Boehringer Ingelheim Venture Fund

Description:

The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.

Total Funding Amount:

43M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Essen, Nordrhein-Westfalen, Germany

Founded Date:

2005-01-01

Contact Email:

info(AT)abalos-tx.com

Founders:

Karl Lang, Philipp Lang

Number of Employees:

11-50

Last Funding Date:

2021-10-14

IPO Status:

Private

Industries: